TOP > 外国特許検索 > BIOMARKER FOR FIBROSIS EVALUATION, EVALUATION METHOD FOR FIBROSIS, AND BACTERIAL CULTURE MEDIUM FOR EVALUATION

BIOMARKER FOR FIBROSIS EVALUATION, EVALUATION METHOD FOR FIBROSIS, AND BACTERIAL CULTURE MEDIUM FOR EVALUATION

外国特許コード F170009239
整理番号 (S2016-0508-N0)
掲載日 2017年9月21日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP008579
国際公開番号 WO 2017150720
国際出願日 平成29年3月3日(2017.3.3)
国際公開日 平成29年9月8日(2017.9.8)
優先権データ
  • 特願2016-041740 (2016.3.4) JP
発明の名称 (英語) BIOMARKER FOR FIBROSIS EVALUATION, EVALUATION METHOD FOR FIBROSIS, AND BACTERIAL CULTURE MEDIUM FOR EVALUATION
発明の概要(英語) [Problem] To provide an evaluation method for fibrosis and a biomarker for fibrosis evaluation.
[Solution] A biomarker for fibrosis evaluation, the biomarker being for detection in biological samples obtained from test animals and including at least one type of bacteria selected from the group the consists of Christensenella , Clostridium , Halomonas , and Shewanella . The fibrosis may include, for example, pulmonary fibrosis (including IPF), renal fibrosis, or the like.
従来技術、競合技術の概要(英語) BACKGROUND ART
In certain tissue fibrosis, fibrosis often lose the original function of the known. Among these as occurring in the lung, idiopathic pulmonary fibrosis (Idiopathic pulmonary fibrosis: hereinafter, referred to as' IPF ') is. IPF is, progressive lethal disease. The median survival after a definitive diagnosis of IPF is -4 years and 2 years, the prognosis of the cancer is worse than normal. For the pathology consists IPF has not been determined, the treatment improved survival is not known. And the gun between IPF, clinical course and disease pathogenesis, in point similar to the behavior of the molecule. Is IPF patients and cancer patients, strongly resistant to treatment, survival period is short. In addition, environmental factors (for example, tobacco) lethal exposed to a, or delay of apoptosis with common molecular abnormalities μA. However, the treatment of cancer patients IPF similarities with the patient submitted hypothesis is not described. On the other hand, the environmental factors such bacteria, and the host response or pathological factors and is not one of the indications. The amount of bacteria in lung lavage fluid for correlation with the progression of pulmonary fibrosis is studies. According to that study, the amount of bacteria (particularly S. Streptococcus, genus Staphylococcus) often in patients with fast progression of the pathological condition, acute exacerbations frequently occurred and the like have been reported (non-patent document 1). In addition, the amount of the bacteria in the bronchial pulmonary fibrosis in lung lavage fluid and a comparison was made between healthy subjects (non-patent document 2) is present in the article. According to this paper, the bronchial pulmonary fibrosis in lung lavage fluid obtained from a patient is, only the species is also detected in healthy subjects have been observed. At this time, bacteria in the lung tissue has not been studied. Kristen senella organism according to the present invention is, in the intestine has been detected from the (non-patent document 3) report. Halomonas organism is, in a person's blood and report detected from the (non-patent document 4, 5) as the inspection method of the flora, reach up to the method and the oligo type (non-patent document 6), to a method of visualizing bacteria (non-patent document 7) have been known.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • MIE UNIVERSITY
  • 発明者(英語)
  • GABAZZA, Esteban
  • GABAZZA, Corina
  • CANN, Isaac
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
さらに詳しい情報をご要望の方は、下記「問合せ先」までお問い合わせください。未公開情報等の交換をおこなう場合は秘密保持契約を締結しての面談等にて対応しております。

PAGE TOP

close
close
close
close
close
close